| Literature DB >> 21612615 |
Andrea Polito1, Jean-Philippe Brouland, Raphael Porcher, Romain Sonneville, Shidasp Siami, Robert D Stevens, Céline Guidoux, Virginie Maxime, Geoffroy Lorin de la Grandmaison, Fabrice C Chrétien, Françoise Gray, Djillali Annane, Tarek Sharshar.
Abstract
INTRODUCTION: The effect of hyperglycaemia on the brain cells of septic shock patients is unknown. The objective of this study was to evaluate the relationship between hyperglycaemia and apoptosis in the brains of septic shock patients.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21612615 PMCID: PMC3218997 DOI: 10.1186/cc10244
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Patients' characteristics
| Whole population | |
|---|---|
| Women (%) | 6 (35) |
| Age (years) | 68 (53 to 72) |
| Cerebrovascular risk factors (%) | 11 (65) |
| Diabetes (%) | 4 (24) |
| Medical admission | 11 (65) |
| Site of infection | |
| Lung only (%) | 9 (53) |
| Abdominoperitoneal only (%) | 0 |
| Urinary tract only (%) | 0 |
| Cellulitis only (%) | 5 (29) |
| > 1 site | 5 (18) |
| Unknown | 0 |
| Positive culture at any site (%) | |
| Gram-positive only (%) | 4 (24) |
| Gram-negative only (%) | 6 (35) |
| Fungus only (%) | 0 |
| Mixed (%) | 7 (411) |
| Positive blood culture (%) | 4 (24) |
| SAPS-II at admission | 43 (30 to 58) |
| Highest OSF score during ICU stay | 4 (4 to 5) |
| Duration of septic shock (days) | 4 (2 to 10) |
| Cumulative time spent with MAP < 60 mm Hg (h) | 11 (4 to 25) |
| Lowest SAP (mm Hg) | 57 (33 to 66) |
| Lowest PaO2 (kPa) | 8.1 (6.1 to 9.0) |
| Lowest SaO2 (%) | 85 (73 to 90) |
| Highest blood sodium level (mmol/L) | 139 (135 to 149) |
| Lowest blood sodium level (mmol/L) | 132 (128 to 137) |
| Lowest BG (gr/l) | 0.6 (0.3 to 1.1) |
| Highest BG (gr/l) | 3.5 (3.3 to 5.4) |
| Δmax BG (gr/l) | 3.4 (2.1 to 4.8) |
| Mean BG (gr/l) | 2.2 (1.4 to 2.8) |
| Patients with hypoglycaemia (%) | 5 (29) |
| Patients with hyperglycaemia (%) | 15 (88) |
| Patients with prolonged hyperglycaemia (%) | 9 (53) |
| Patients treated with insulin (%) | 6 (35) |
| Neuronal apoptosis | 1.0 (1.0 to 2.0) |
| Microglial apoptosis | 1.0 (1.0 to 1.5) |
| GFAP expression | 2.0 (2.0 to 3.0) |
| HLA-DR expression | 1.0 (1.0 to 2.0) |
| CD68 expression | 1.0 (0.5 to 1.5) |
| Glial TNF-α expression | 1.0 (0 to 1.0) |
| iNOS expression | 1.0 (1.0 to 1.0) |
| Neuronal GLUT4 | 1.5 (1.0 to 2.0) |
| Microglial GLUT5 | 1.0 (0.5 to 1.0) |
| CD68 | 1.5 (1.0 to 2.0) |
| Beta-APP | 1.0 (1.0 to 1.5) |
Beta APP, beta-amyloid precursor protein; BG, blood glucose; CD68, Cluster of Differentiation; GFAP, Glial Fibrillary Acid Protein; GLUT, glucose transporter; HLA-DR, Major Histocompatibility Complex Class II cell surface receptor; ICU, intensive care unit; iNOS, inducible Nitric Oxide Synthase; MAP, mean arterial pressure; OSF, organ systemic failure; PaO2, partial pressure of oxygen in arterial blood; SAP, systolic arterial pressure; SAPS-II, simplified acute physiology score; SaO2, saturation of oxygen in arterial blood; TNFα, tumor necrosis factor alpha.
Association of the area under the BG curve above 2 g/l with clinical characteristics and neuropathological findings
| Spearman ρ (95%CI) |
| |
|---|---|---|
| SAPS-II at admission | 0.34 (-0.17 to 0.71) | 0.18 |
| Knauss | -0.21 (-0.63 to 0.30) | 0.43 |
| McCabe | 0.05 (-0.44 to 0.52) | 0.85 |
| Neuronal ischaemia | 0.05 (-0.43 to 0.53) | 0.82 |
| Gliosis | 0.15 (-0.36 to 0.59) | 0.57 |
| GFAP expression | 0.11 (-0.39 to 0.56) | 0.67 |
| HLA-DR expression | 0.06 (-0.43 to 0.53) | 0.81 |
| CD68 expression | 0.44 (-0.05 to 0.76) | 0.08 |
| Beta-APP expression | 0.61 (0.06 to 0.88) | 0.03 |
| Neuronal apoptosis | 0.53 (0.07 to 0.81) | 0.028 |
| Microglial apoptosis | 0.70 (0.33 to 0.88) | 0.002 |
| Glial TNFα expression | -0.04 (-0.51 to 0.45) | 0.86 |
| Endothelial iNOS expression | 0.04 (-0.45 to 0.51) | 0.87 |
Each neuropathological finding was score from 0 to 3 (see methods). beta-APP, beta-amyloid precursor protein; CD68, Cluster of Differentiation; GFAP, glial fibrillary acidic protein; HLA-DR, Major Histocompatibility Complex Class II cell surface receptor; iNOS, inducible Nitric Oxide Synthase; TNFα, tumor necrosis factor alpha.
Figure 1Neuronal and microglial apoptosis in cerebral amygdale. Case 7359, Cerebral amygdala. The back arrows show two apoptotic neurons with darkly stained nucleus. The red arrow shows an apoptotic microglial cell with a dark nucleus. The cytoplasm of the apoptotic cells is also stained corresponding to disintegration of nuclear chromatin into apoptotic bodies. (ISEL ×800).
Figure 2Axonal damage in the hippocampal white matter. Cortico-subcortical junction in the hippocampus. Black arrows show axonal swellings in the white matter. These represent the accumulation of the precursor of the beta-amyloid protein due to alteration of the axonal flow. (APP imunostaining ABC/peroxidase/DAB x25).
Figure 3Hippocampal expression of GLUT4. Hippocampal interneurons in CA1 and CA4 exhibit a homogeneous cytoplasmic staining (arrow) with GLUT4 antibody (ABC/peroxidase/DAB, x40).
Figure 4Hippocampal expression of GLUT5. In hippocampal interneurons (CA1 and CA4), microglial cells are strongly stained (arrows) whereas neurons are not labelled with GLUT5 antibody (ABC/peroxidase/DAB, x25).
Association of neuronal GLUT4 and microglial GLUT5 expression with glycaemia and cell apoptosis
| Spearman ρ (95% CI) | Neuronal GLUT4 expression |
| Microglial GLUT5 expression |
|
|---|---|---|---|---|
| Area under the BG curve > 2 g/l | -0.006 (-0.49 to 0.48) | 0.98 | 0.03 (-0.46 to 0.50) | 0.91 |
| Neuronal apoptosis | -0.29 (-0.68 to 0.22) | 0.25 | -0.40 (-0.74 to 0.10) | 0.11 |
| Microglial apoptosis | -0.002(-0.48 to 0.48) | 0.99 | -0.25 (-0.65 to 0.26) | 0.33 |
Each neuropathological finding was score from 0 to 3 (see methods). BG, blood glucose; GLUT, glucose transporter.